Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Diffuse Large B Cell Lymphoma Similar Videos
-
Future use of CD19 CAR T-cells beyond relapsed DLBCL_Jean Koff, MD, MS; #DDHO2021
3:22
-
Module 4_Integrating Novel Approaches in Clinical Practice & Key Takeaways_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
19:16
-
Beyond the Congress Video Edits Nina Shah_recap_#BeyondASH21recap
4:20